IQVIA Holdings Inc
NYSE:IQV
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
137
244.29
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
IQV
stock under the Base Case scenario is
284.06
USD.
Compared to the current market price of 237.68 USD,
IQVIA Holdings Inc
is
Undervalued by 16%.
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for IQVIA Holdings Inc.
Fundamental Analysis
IQV Profitability Score
Profitability Due Diligence
Score
IQV Solvency Score
Solvency Due Diligence
Score
Select up to 3 indicators:
Select up to 3 indicators:
Potential slowdown in funding for new clinical trials could hurt IQVIA’s contract research segment, especially if biopharma clients tighten budgets to preserve cash amid economic or regulatory uncertainties.
Increasing competition from integrated contract research organizations and large data analytics players may erode IQVIA’s market share, pressuring both pricing and profitability of its technology solutions.
Intensifying regulatory scrutiny around patient data privacy and real-world evidence collection could add compliance costs and limit IQVIA’s ability to monetize proprietary datasets effectively.
IQVIA’s leadership in combining advanced analytics with its vast healthcare data sets positions it to capture rising demand for real-world evidence and personalized medicine insights in a rapidly evolving industry.
The company’s diversified revenue streams, spanning clinical research and technology-enabled services, can smooth out potential downturns in any single segment and drive steady long-term growth.
Ongoing digital transformation initiatives in life sciences firms provide cross-selling opportunities for IQVIA’s cloud-based platforms, fostering deeper client relationships and increasing high-margin service adoption.
Revenue & Expenses Breakdown
IQVIA Holdings Inc
Balance Sheet Decomposition
IQVIA Holdings Inc
IQVIA Holdings Inc
Free Cash Flow Analysis
IQVIA Holdings Inc
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
IQVIA Holdings Inc
Wall St
Price Targets
IQV Price Targets Summary
IQVIA Holdings Inc
According to Wall Street analysts, the average 1-year price target for
IQV
is 261.83 USD
with a low forecast of 217.15 USD and a high forecast of 304.5 USD.
Dividends
Current shareholder yield for
IQV is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
IQV
stock under the Base Case scenario is
284.06
USD.
Compared to the current market price of 237.68 USD,
IQVIA Holdings Inc
is
Undervalued by 16%.